Company news

Oryzon Genomics SA news in 2024

Oryzon Genomics SA's news releases, calls and decks from 2024, newest first.

View company

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024

October 24, 2024

ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress

September 23, 2024

ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder

September 11, 2024

ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia

September 9, 2024

ORYZON to Provide Corporate Progress Updates at Several Events in September

August 29, 2024

ORYZON reports financial results and corporate update for half-year ending June 30, 2024

July 31, 2024

ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan

July 8, 2024

ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders

June 28, 2024

ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024

June 14, 2024

ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology

June 3, 2024

ORYZON to Provide Corporate Progress Updates at Several Events in June

May 30, 2024

ORYZON Announces U.S. FDA Clearance of CTEP-CRADA Phase I/II Clinical Trial Sponsored by NCI for Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer

April 8, 2024

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

February 26, 2024

ORYZON to Provide Corporate Progress Updates at Several Events in February-March

February 5, 2024

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

January 19, 2024

ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)

January 5, 2024

ORYZON to Provide Corporate Progress Updates at Several Events in January

January 3, 2024

Decks in 2024